- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12.25 | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential | 3 | Investing.com | ||
| 17.12.25 | Upstream Bio: Mizuho startet Coverage mit "Outperform" dank Potenzial bei Asthma-Medikament | - | Investing.com Deutsch | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Upstream Bio, Inc. reports Q3 results | 2 | Seeking Alpha | ||
| 05.11.25 | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 219 | GlobeNewswire (Europe) | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| 05.11.25 | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 3 | Investing.com | ||
| 14.10.25 | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com | ||
| 14.10.25 | Upstream Bio: Truist Securities startet Coverage mit Kaufempfehlung dank Potenzial bei Atemwegsmedikament | 1 | Investing.com Deutsch | ||
| 30.09.25 | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 416 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| 09.09.25 | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09.25 | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09.25 | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 8 | RTTNews | ||
| 26.08.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 2 | Investing.com | ||
| 08.07.25 | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 345 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| 20.05.25 | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 185 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| 01.04.25 | Pre-market Movers: Marblegate Acquisition Corp., iCoreConnect, Hyperscale Data, Upstream Bio, InnovAge Holding | 604 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green Marblegate Acquisition Corp. (GATE) is up over 55%... ► Artikel lesen | |
| 12.03.25 | Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 209 | GlobeNewswire (Europe) | - Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 - - Completed upsized IPO... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 81,26 | -3,09 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,72 | -0,29 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 36,850 | -1,15 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 26,340 | +0,77 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| QIAGEN | 43,845 | 0,00 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| ALUMIS | 26,350 | -2,55 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TARSUS PHARMACEUTICALS | 63,51 | -5,01 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,910 | -0,29 % | MEDICAL BioHealth Fonds: Eli Lilly kauft Ventyx Biosciences | Gräfelfing (www.fondscheck.de) - Anbei eine aktuelle Pressemitteilung der Medical Strategy GmbH:Zum Kauf von Ventyx Biosciences durch Eli Lilly ein Statement von Mario Linimeier, Geschäftsführer der... ► Artikel lesen | |
| ERASCA | 11,240 | +6,19 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ARCUTIS BIOTHERAPEUTICS | 26,070 | -0,46 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 43,520 | -3,20 % | Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout | ||
| APOGEE THERAPEUTICS | 64,84 | -5,88 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| EVOTEC | 6,346 | 0,00 % | Puma-Übernahme wird konkreter! Als nächstes Evotec und Silver Viper Aktien kaufen? | Schon länger gibt es Übernahmespekulationen rund um Puma. Jetzt hat sich Anta 29 % am deutschen Sportartikelkonzern gesichert. Dafür zahlen die Chinesen 35 EUR je Aktie. An der Börse hält sich die Euphorie... ► Artikel lesen | |
| CG ONCOLOGY | 51,94 | -1,18 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen |
Das Unternehmen UPSTREAM BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,77 % bei einem Aktienkurs von 29,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.